文献速递消化系统肿瘤

转移性结直肠癌的单核苷酸变异、肿瘤突变负荷与微卫星不稳定性:FIRE-3试验二代测序结果

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
PubMed 文献 · Eur J Cancer · 2020-08-15

结果显示RAS、BRAF V600E和SMAD4突变与较差预后相关,SMAD4突变可能预测西妥昔单抗疗效,MSI-H肿瘤的客观缓解率、无进展生存和总生存数值上较低。

要点

  • RAS、BRAF V600E和SMAD4突变是FIRE-3试验中的不良预后生物标志物。
  • SMAD4突变可能对西妥昔单抗疗效具有预测意义。
  • MSI-H肿瘤的ORR、OS和PFS数值上较低。

核心结论

  • RAS、BRAF V600E和SMAD4突变被确定为FIRE-3试验患者的不良预后生物标志物,而BRAF非V600E突变患者观察到结局改善。
  • SMAD4突变可能为西妥昔单抗疗效提供预测相关性。
  • MSI-H肿瘤显示数值上较低的ORR、OS和PFS。

研究设计与样本

  • 采用FoundationOne®二代测序识别单核苷酸变异、拷贝数变异、高肿瘤突变负荷(TMB-H)和高微卫星不稳定性(MSI-H)。
  • 数据与客观缓解率、无进展生存和总生存进行相关性分析。

主要发现

  • 常见单核苷酸变异包括TP53、APC、KRAS、PIK3CA、BRAF、SMAD4和FBXW7。
  • KRAS、BRAF V600E和SMAD4突变通过逻辑惩罚回归对ORR确认为预后生物标志物。
  • SMAD4野生型肿瘤患者OS显著长于SMAD4突变肿瘤患者(HR=0.59,95%CI 0.34-1.01,p=0.05),接受西妥昔单抗治疗时ORR概率更高(SMAD4 SNV vs WT的OR=0.32,95%CI 0.10-0.98,p=0.05)。
  • FBXW7突变富集MSI-H(30.0%,p=0.03)和TMB-H(17.3%,p=0.003)肿瘤。
  • MSI-H肿瘤观察到数值上较低的ORR、OS和PFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable precision oncology. MATERIAL AND METHODS: FoundationOne® next-generation sequencing identified single-nucleotide variants (SNVs), copy number alterations, high TMB (TMB-H) and high-grade microsatellite instability (MSI-H) in patients treated in the FIRE-3 trial. Data were correlated with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: Three hundred seventy-three (49.6%) of 752 patients provided material for this analysis. Frequent SNVs included TP53, APC, KRAS, PIK3CA, BRAF, SMAD4 and FBXW7. KRAS, BRAF V600E and SMAD4 mutations were confirmed as prognostic biomarkers by logistic penalised regression for ORR. OS was significantly longer in patients with SMAD4 wild-type (WT) tumours than in those with SMAD4-mutated tumours (hazard ratio = 0.59 [95% confidence interval {CI} = 0.34-1.01], p = 0.05), with a higher probability of ORR [odds ratio, SMAD4 SNV versus WT = 0.32 [95% CI = 0.10-0.98], p = 0.05] when treated with cetuximab. MSI-H (30.0%, p = 0.03) and TMB-H (17.3%, p = 0.003) tumours were enriched by FBXW7 mutations. Numerically lower ORR, OS and PFS were observed in MSI-H tumours. CONCLUSIONS: RAS, BRAF V600E and SMAD4 mutations were identified as poor prognostic biomarkers in patients of the FIRE-3 trial, whereas improved outcome was observed for BRAF non-V600E mutation. SMAD4 mutation might provide predictive relevance for cetuximab efficacy. MSI-H tumours showed numerically lower ORR, OS and PFS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stahler A, Stintzing S, von Einem JC, et al. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. Eur J Cancer. 2020. PMID: 32810748. doi:10.1016/j.ejca.2020.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。